Supplementary data: Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study

These are peer-reviewed supplementary materials for the article 'Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study' published in the Journal of Comparative Effectiveness Research.
Supplementary Table 1: Demographics and comorbidities in the risk-set sampled population of patients with CRSwNP with FESS vs no FESSSupplementary Table 2: Medication use and HCRU during the baseline period in the risk-set sampled population of patients with CRSwNP with FESS vs no FESSSupplementary Table 3: Change in cumulative OCS dose from baseline to follow-up among baseline OCS users* in the PS-matched population of patients with CRSwNP with FESS vs no FESSSupplementary Table 4: All-cause costs during the intervention in the PS-matched population of patients with CRSwNP with FESS vs no FESSSupplementary Table 5: Cumulative OCS dose during follow-up in patients with or without asthma subgroup from the PS-matched population of patients with CRSwNP with FESS vs no FESSSupplementary Table 6: Procedural code list for functional endoscopic sinus surgery (FESS) exposureSupplementary Figure 1: Study designSupplementary Appendix 1: Propensity score (PS) matchingAim: To compare oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps undergoing functional endoscopic sinus surgery (FESS; intervention) versus not undergoing FESS. Materials & methods: Retrospective cohort study using US claims data (Optum’s de-identified Clinformatics R ? Data Mart Database; 2011–2021). Groups were propensity score (PS) matched to adjust for confounding. OCS burden (cumulative dose in mg prednisone equivalents) and HCRU were assessed during baseline (365 days pre-index), intervention (days 0–44), and follow-up (days 45–365); costs during intervention and follow-up. Results: Before PS-matching, both groups had substantial comorbidity burden (>50% allergic rhinitis; >25% asthma) and over half of patients had used OCS (65% [FESS] vs 52% [non-FESS]; p < 0.01). After PS-matching (n = 8909 per group), OCS cumulative dose during follow-up was 18% lower among FESS versus non-FESS patients (mean difference: -40 mg per patient [95% CI: -57, -23; p < 0.01]). Similar proportions of patients filled OCS prescriptions during follow-up (35% [FESS], 36% [non-FESS]) and in these patients, OCS burden remained high (mean [SD] cumulative dose 521 [786] vs 612 [906] mg, respectively). Mean total healthcare costs per patient during the intervention period were $28,832 (FESS) and $2537 (non-FESS), but similar during follow-up ($15,659 and $15,926, respectively). HCRU was similar in follow-up, except more FESS patients visited an otolaryngologist (57% vs 32%, p < 0.01). Conclusion: In US clinical practice, OCS burden in patients with chronic rhinosinusitis with nasal polyps was significantly lower but remained substantial following FESS, and HCRU and costs during follow-up were similar to matched patients without FESS.